Biotechnology is of outstanding importance to pharmaceutical research. An increasing number of innovative medicines have their origin in biotechnological research, such as the use of living organisms or their derivatives for therapeutic purposes, rather than chemical substances as in traditional medicines. As these products are extremely complicated and expensive to develop and test, Europe needs to create an environment that rewards innovation and removes unnecessary regulatory, administrative, or economic obstacles.
Key Enabling Technologies: a significant part of future goods and services are as yet unknown, but the main driving force behind their development will be Key Enabling Technologies (KETs), such as nanotechnology, micro- and nanoelectronics including semiconductors, advanced materials, biotechnology and photonics. These technologies enable the development of new goods and services and the restructuring of industrial processes needed to modernise EU industry and make the transition to a knowledge-based and low carbon resource-efficient economy.
EU Life Sciences and Biotechnology related Policies".